Literature DB >> 34280019

Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.

Ashley L Cunningham1, Orhi Esarte Palomero1, Bradley J Voss2, M Stephen Trent2,3, Bryan W Davies1.   

Abstract

Otilonium bromide is a poorly absorbed oral medication used to control irritable bowel syndrome. It is thought to act as a muscle relaxant in the intestine. Here, we show that otilonium bromide has broad-spectrum antibacterial and antifungal activity, including against multidrug-resistant strains. Our results suggest otilonium bromide acts on enteric pathogens and may offer a new scaffold for poorly absorbed intestinal antimicrobial therapy.

Entities:  

Keywords:  antibacterial; antifungal; otilonium bromide

Mesh：

Substances：

Year:  2021        PMID： 34280019      PMCID： PMC8448155          DOI： 10.1128/AAC.00443-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Bacterial target sites for biocide action.

Authors:  J-Y Maillard
Journal:  J Appl Microbiol       Date:  2002       Impact factor: 3.772

2.  The clinical pharmacology of single doses of otilonium bromide in healthy volunteers.

Authors:  J A Sutton; S G Kilminster; G P Mould
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 3.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Authors:  Fabiane Klem; Akhilesh Wadhwa; Larry J Prokop; Wendy J Sundt; Gianrico Farrugia; Michael Camilleri; Siddharth Singh; Madhusudan Grover
Journal:  Gastroenterology       Date:  2017-01-06       Impact factor: 22.682

Review 4.  The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside.

Authors:  G T Cole; A A Halawa; E J Anaissie
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

5.  Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Joanna E Rimmer; Clayton Harro; David A Sack; Kawsar R Talaat; Ramiro L Gutierrez; Barbara DeNearing; Jessica Brubaker; Renee M Laird; Frédéric Poly; Alexander C Maue; Kayla Jaep; Ashley Alcala; Yelizaveta Mochalova; Christina L Gariepy; Subhra Chakraborty; Patricia Guerry; David R Tribble; Chad K Porter; Mark S Riddle
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

6.  Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon.

Authors:  P Santicioli; V Zagorodnyuk; A R Renzetti; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-05       Impact factor: 3.000

7.  Hemolysis of erythrocytes by antibacterial preservatives. II. Quaternary ammonium salts.

Authors:  D E Cadwallader; H C Ansel
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

Review 8.  The emerging world of the fungal microbiome.

Authors:  Gary B Huffnagle; Mairi C Noverr
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

Review 9.  Decolonization in Prevention of Health Care-Associated Infections.

Authors:  Edward J Septimus; Marin L Schweizer
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

10.  Quaternary salts of substituted 2-aminoethyl N-benzoylaminobenzoate. A new class of smooth muscle relaxant agents.

Authors:  M Ghelardoni; V Pestellini; N Pisanti; G Volterra
Journal:  J Med Chem       Date:  1973-09       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.